Navigation Links
2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
Date:12/13/2007

CLEVELAND, Ohio, December 13 /PRNewswire/ -- Ten new validation studies were published during 2007 on the Simbionix Mentor series of training simulators, bringing the total number of studies published to 65.

"This year we have seen a considerable increase in interest from US and European institutes" said Gary Zamler, Simbionix' CEO. "Some of the world's most highly respected academic medical institutions and teaching hospitals have completed studies measuring the efficacy of using Simbionix Mentor simulation products."

The studies published this year include two new studies on the GI Mentor, two on the URO/PERC platform, three on the LAP Mentor and three on the ANGIO Mentor. Some of the studies were carried out at multiple sites, something that typically increases the reliability of study results. The institutes which conducted studies include the University of Texas, Catharina Hospital of the Netherlands, the British Imperial College of London and the Graduate School of Medical Sciences in the Kyushu University of Fukuoka, the first study by a Japanese institute to date.

The study carried out by experts at Catharina Hospital's Department of Gastroenterology concluded that the GI Mentor II simulator offered a convincing, realistic representation of colonoscopy that can discriminate between different levels of colonoscopy expertise. As a result, the product was granted both construct validity and expert validity. The study carried out by Kyushu University of Fukuoka concluded that the LAP Mentor was able to differentiate between subjects with different laparoscopic experience.

One of the key value points for medical institutions to use Simbionix products is the ability to offer clinicians and medical students the required hands-on surgical experience at zero patient risk. Validation studies are critical to prove the efficacy of the simulation experience, so that institutions can rely on simulators to advance clinician training and improve patient safety. Yael Friedman Ph.D., Simbionix Chief Scientist over Medical Projects noted "We are happy to see that all of the institutes which have validated our products continue to demonstrate the effectiveness and advantage of using our Mentor products for surgical training".

Full details of the validation tests carried out can be seen on Simbionix website:

- For LAP Mentor validation tests, see http://www.simbionix.com/Media_validation_LAP.html

- For ANGIO Mentor validation tests, see http://www.simbionix.com/Media_validation_ANGIO.html

- For GI Mentor validation tests, see http://www.simbionix.com/Media_validation.html

- For URO Mentor validation tests, see http://www.simbionix.com/Media_validation_URO.html

About Simbionix USA Corporation

Simbionix is the industry leader in the development of innovative and effective medical simulation products used for clinical education and training of medical professionals. Simbionix products are designed to accelerate best-practice medical training, advance clinical performance and improve patient safety. The company is committed to continuously innovating and broadening its product offerings with a wide range of training modules, case studies and scenarios, developed in response to the growing importance of clinical training and education as a means of achieving improved patient care.
Additional company information can be found at http://www.simbionix.com

Contact:

Inbal Mazor,

VP Marketing,

mailto:inbal@simbionix.com,

+1-216-229-2040


'/>"/>
SOURCE Simbionix Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
2. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
3. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
4. Life on Mars pregnancy test successfully launched
5. Of mice and men: new male contraceptives successful in rodents and humans
6. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
7. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
8. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
9. James Webb Space Telescope marks successful completion
10. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):